Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
British Journal of Clinical Pharmacology
|
April 3, 2016
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials
Oneeb Majid, Antonio Laurenza, Jim Ferry, et al.
Epilepsy Research
|
December 24, 2018
Potential protein-binding displacement interactions with perampanel: An in vitro analysis
Barry E Gidal, Jim Ferry, Antonio Laurenza, et al.
Trends in Pharmacological Sciences
|
March 25, 2025
M1 receptor positive allosteric modulators discovery approaches
Takao Mandai, Arthur A Simen, Antonio Laurenza, et al.
Epilepsy & Behavior : E&B
|
June 10, 2015
Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies
David Ko, Haichen Yang, Betsy Williams, et al.
Epilepsia
|
June 23, 2015
Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures
Blanca Vazquez, Haichen Yang, Betsy Williams, et al.
Epilepsy & Behavior Case Reports
|
May 1, 2018
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Patrick Kwan, Scott Mintzer, Antonio Laurenza, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 4, 2020
In Vitro Metabolism of Slowly Cleared G Protein-Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism
Amin Kamel, Steve Bowlin, Natalie Hosea, et al.
Epilepsy Research
|
May 20, 2015
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies
Antonio Laurenza, Haichen Yang, Betsy Williams, et al.
Epilepsy Research
|
June 20, 2015
Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials
Haichen Yang, Antonio Laurenza, Betsy Williams, et al.
Epilepsy Research
|
June 20, 2015
Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel
Georgia Montouris, Haichen Yang, Betsy Williams, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
British Journal of Clinical Pharmacology
|
April 3, 2016
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials
Oneeb Majid, Antonio Laurenza, Jim Ferry, et al.
Epilepsy Research
|
December 24, 2018
Potential protein-binding displacement interactions with perampanel: An in vitro analysis
Barry E Gidal, Jim Ferry, Antonio Laurenza, et al.
Trends in Pharmacological Sciences
|
March 25, 2025
M1 receptor positive allosteric modulators discovery approaches
Takao Mandai, Arthur A Simen, Antonio Laurenza, et al.
Epilepsy & Behavior : E&B
|
June 10, 2015
Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies
David Ko, Haichen Yang, Betsy Williams, et al.
Epilepsia
|
June 23, 2015
Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures
Blanca Vazquez, Haichen Yang, Betsy Williams, et al.
Epilepsy & Behavior Case Reports
|
May 1, 2018
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Patrick Kwan, Scott Mintzer, Antonio Laurenza, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 4, 2020
In Vitro Metabolism of Slowly Cleared G Protein-Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism
Amin Kamel, Steve Bowlin, Natalie Hosea, et al.
Epilepsy Research
|
May 20, 2015
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies
Antonio Laurenza, Haichen Yang, Betsy Williams, et al.
Epilepsy Research
|
June 20, 2015
Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials
Haichen Yang, Antonio Laurenza, Betsy Williams, et al.
Epilepsy Research
|
June 20, 2015
Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel
Georgia Montouris, Haichen Yang, Betsy Williams, et al.
Page
of 5